Why Can Two PRP Blood Preparations Be Different?

Why isn't every PRP mixture alike?

The finished mixture may have different amounts of platelets, white blood cells, and red blood cells because clinics use different tools and may spin the blood for different lengths of time. A higher platelet amount doesn't prove that the joint will feel better.

There isn't one mixture known to fit every sore joint.

The body area and your health matter too. Research on one mixture or one joint may not answer a question about another. Concentrated PRP means prepared blood with more platelets, but the name doesn't tell you how many or which other blood cells remain.

Which PRP questions will help during the visit?

Start with a movement you want to regain. Ask why this PRP mixture may fit that goal. The answer needs to address your joint, not merely repeat the treatment name.

Have the clinic explain how it prepares the blood and what remains after spinning. Ask whether research on that mixture involved the same joint. Then ask what doctors still don't know about the likely relief or risks for you.

Find out what happens before and after the care. Learn how the clinic checks progress, what the total cost may be, and which choices remain if soreness doesn't ease.

What if the soreness hasn't settled and you want to discuss PRP?

QC Kinetix uses medical providers as its name for exam staff, so ask if you'll meet a doctor, nurse, or another member of the team. The clinic's regenerative treatments are non-surgical choices made by drawing your blood, preparing it there, and putting that portion inside the aching joint.

Its natural pain treatments include PRP and concentrated PRP. Joint preservation means discussing such care before an operation, including alternatives to surgery on your knee or hip. When the clinic says improve quality of life, name the exact activity you hope to do more easily.

Ask what the clinic will watch after care. Find out who answers if soreness grows and whether you'll need another visit. The answer also needs to cover your other choices.

Evidence sources

1. A meta-analysis of 18 Level I trials (811 PRP vs 797 HA patients, mean follow-up 11.1 months) found mean WOMAC total improvement of 44.7% with PRP versus 12.6% with HA (P<.01). Six of 11 VAS-based studies and 3 of 6 IKDC-based studies favoured PRP significantly. In the subanalysis, leukocyte-POOR PRP was associated with significantly better subjective IKDC scores than leukocyte-rich PRP.

   Belk JW, et al. — Platelet-Rich Plasma Versus Hyaluronic Acid for Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.. American Journal of Sports Medicine, 2021.

2. A double-blind randomized trial allocated 192 patients with KL 1-3 knee OA to three weekly injections of leukocyte-RICH or leukocyte-POOR PRP (mean leukocyte concentration 7,991 x10^6/L vs 0.1 x10^6/L). No difference was found in any clinical score at 2, 6 or 12 months (IKDC improved 45.6 to 60.7 vs 46.8 to 62.9; P=.626). Mild adverse events were numerically more frequent with leukocyte-rich PRP (12.2% vs 4.7%) but not significantly so.

   Di Martino A, et al. — Leukocyte-Rich versus Leukocyte-Poor Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Double-Blind Randomized Trial.. American Journal of Sports Medicine, 2022.

3. A systematic review of 32 studies comparing leukocyte-poor and leukocyte-rich PRP in knee OA found both formulations improved pain and function above the MCID with no significant difference between them at 3, 6 or 12 months - but leukocyte-RICH PRP carried significantly higher odds of post-injection pain (OR 1.64; 95% CI 1.29-2.10) and swelling (OR 1.56; 95% CI 1.22-1.99).

   Kim JH, et al. — Adverse Reactions and Clinical Outcomes for Leukocyte-Poor Versus Leukocyte-Rich Platelet-Rich Plasma in Knee Osteoarthritis: A Systematic Review and Meta-analysis.. Orthopaedic Journal of Sports Medicine, 2021.

4. A 2026 network meta-analysis of 21 RCTs (2,254 patients) found both leukocyte-rich and leukocyte-poor PRP significantly superior to placebo and to hyaluronic acid for function at 6-12 months (MD vs placebo -13.20 and -10.54 respectively). LP-PRP ranked highest (P-score 0.96) but the DIRECT comparison between the two formulations showed no statistically significant difference, and the authors concluded there is insufficient evidence to recommend one PRP formulation over the other.

   Xu B, et al. — Leukocyte-rich versus leukocyte-poor platelet-rich plasma and hyaluronic acid for knee osteoarthritis: a systematic review and network meta-analysis.. Journal of Orthopaedic Surgery and Research, 2026.

5. A 2026 systematic review of leukocyte-rich versus leukocyte-poor PRP for osteoarthritis concluded the current evidence is insufficient to determine whether adding leukocytes provides any clinical benefit, that results generally show no significant difference between the two, and that there is no conclusive evidence local reactions are caused by leukocytes specifically.

   Martin-Vega M, et al. — Leukocyte-rich versus leukocyte-poor platelet-rich plasma for Osteoarthritis: A systematic review.. Regenerative Therapy, 2026.

6. Blood from seven donors was processed through five commercial PRP systems (Arthrex Angel, Emcyte Genesis CS, Arteriocyte Magellan, Harvest SmartPrep, Biomet GPS III). White-cell concentration ranged from 11.0 to 27.3 thousand/uL between systems, neutrophil concentration from 0.6 to 9.4 thousand/uL, red-cell concentration from under 1.1 to 3.2 million/uL, and pH from 6.95 to over 7.26. The authors advise caution in interpreting clinical PRP results because the product itself differs by device.

   Degen RM, et al. — Commercial Separation Systems Designed for Preparation of Platelet-Rich Plasma Yield Differences in Cellular Composition.. HSS Journal, 2017.

7. A single-donor comparison of five PRP preparations (RegenPRP, Mini GPS III, Selphyl, Arthrex ACP and a laboratory protocol) across ten donors found two systems produced leukocyte-RICH PRP with higher red-cell, white-cell and neutrophil proportions while three produced leukocyte-poor PRP, and that platelet and growth-factor doses varied substantially between devices, with platelet dose positively correlated with every growth factor measured.

   Magalon J, et al. — Characterization and comparison of 5 platelet-rich plasma preparations in a single-donor model.. Arthroscopy, 2014.

8. A meta-analysis with meta-regression of 10 Level I-II studies (696 patients) of PRP augmentation during rotator cuff repair classified trials by whether the platelet concentration factor exceeded a 4-fold increase over whole blood. Neither patient-reported outcomes nor retear rates differed between high-dose and low-dose PRP - a direct test of the 'more platelets is better' premise, which it did not support in this setting.

   Lim JJ, et al. — Platelet Concentration Does Not Influence Clinical Efficacy and Retear Rates of Rotator Cuff Repair With Platelet-Rich Plasma: A Systematic Review and Meta-analysis With Meta-Regression.. American Journal of Sports Medicine, 2026.